Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)
ID: 351095Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351095

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-018.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Nov 21, 2023, 12:00 AM UTC
  4. 4
    Due Feb 23, 2026, 12:00 AM UTC
Description

The National Institutes of Health (NIH) is offering a funding opportunity titled "Miniaturization and Automation of Tissue Chip Systems (MATChS)" aimed at U.S. small business concerns through STTR Phase I and II cooperative agreements. The initiative seeks to develop innovative microphysiological systems (MPS) that replicate human organ functions for drug discovery and biomedical research, addressing the limitations of traditional methods that are often costly and time-consuming. This funding opportunity is crucial for advancing tissue chip technology, enhancing the accessibility and usability of these systems in research, and supporting safe therapeutic assessments. Interested applicants can apply for a total funding commitment of up to $2.15 million, with key submission dates including an open date for applications on January 22, 2024, and a closing date of February 23, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-018.html.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
RFA-TR-23-018-Full-Announcement.html
Aug 24, 2024, 2:22 AM UTC
RFA-TR-23-018.html
Aug 24, 2024, 2:22 AM UTC
The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the Miniaturization and Automation of Tissue Chip Systems (MATChS) funding opportunity. This initiative invites U.S. small business concerns to submit applications for STTR Phase I and II cooperative agreements. The MATChS aims to develop innovative microphysiological systems (MPS) that mimic human organ functions for drug discovery and biomedical research, addressing challenges in traditional methods that are costly and time-consuming. Objectives include creating portable and automated MPS platforms with integrated sensors for high-throughput data analysis. The initiative builds upon previous collaborations between NIH, NCATS, and NASA, enhancing accessibility and usability of tissue chips in research. Key dates include an open date for submissions on January 22, 2024, and a funding commitment of up to $2.15 million for two Phase I awards and one Phase II award in FY 2024. The announcement emphasizes the need for milestone-driven projects with active NIH involvement in their development. Eligible applicants must be organized for profit, have a significant U.S. presence, and meet specific ownership and employee criteria. The MATChS serves to further the field of tissue chip technology, supporting safe and efficient therapeutic assessments while driving towards commercialization and practical application in clinical settings.
Similar Opportunities
Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Miniaturization and Automation of Tissue Chip Systems" (MATChS), aimed at advancing the development of automated and miniaturized microphysiological systems (MPS) for drug discovery and biomedical research. This funding opportunity encourages U.S. small business concerns (SBCs) to propose innovative solutions that enhance the efficiency and reliability of tissue chip technologies, with a focus on reducing complexity and costs while facilitating higher throughput. Approximately $2.15 million is allocated for FY 2024 to support projects that collaborate with NIH staff to achieve defined milestones and pathways to commercialization. Interested applicants must submit their proposals by February 23, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) Grant Applications, inviting eligible U.S. small businesses to submit proposals for innovative projects that align with NIH's research and development mission. This funding opportunity, identified as PA-24-247, specifically excludes clinical trials and aims to foster collaboration between small businesses and research institutions to advance technology development in health-related fields. Eligible applicants must be for-profit small businesses based in the U.S., with budget limits set at $306,872 for Phase I and $2,045,816 for Phase II awards. The application deadline is April 5, 2025, with an initial submission date of September 5, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) grant applications, inviting eligible U.S. small businesses to submit proposals that include at least one clinical trial. This funding opportunity aims to support research and development projects that align with the scientific missions of participating NIH Institutes and Centers, emphasizing the importance of innovation in health-related technologies. Eligible applicants must be U.S.-based small businesses with majority ownership by U.S. citizens or resident aliens, and the grants provide funding caps of up to $306,872 for Phase I and $2,045,816 for Phase II projects. Interested parties should note that the application deadline is April 5, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Research Resource for Human Organs and Tissues (U42 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Resource for Human Organs and Tissues" through a cooperative agreement mechanism (U42), aimed at supporting a program that provides and facilitates the availability of human tissues and organs for biomedical research. The initiative seeks to enhance the procurement, preservation, and distribution of diverse biospecimens, both normal and diseased, to aid researchers in understanding various diseases and addressing public health priorities. Applicants must demonstrate a proven track record in managing a human tissue and organ research resource, with direct costs capped at $720,000 over a potential five-year project period. The application period opens on December 24, 2024, with a submission deadline of September 25, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity for small businesses to develop novel extracellular vesicle (EV)-based therapeutic platforms aimed at regenerative medicine through a cooperative agreement. The primary objective is to support the production, manufacturing, and application of EVs for tissue and organ repair, with a focus on utilizing stem cells for EV generation and ensuring GMP-compliant production. This initiative is critical for advancing therapeutic technologies in regenerative medicine, with funding amounts capped at $295,924 for Phase I and $1,972,828 for Phase II grants, while clinical trials are not permitted under this opportunity. Interested applicants must adhere to strict submission guidelines and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, with the application deadline set for June 6, 2025.
Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) to develop extracellular vesicle (EV)-based therapeutic platforms aimed at regenerative medicine. The primary objective of this funding opportunity announcement (FOA) is to support the production and manufacturing of both native and engineered EVs for tissue and organ repair, with applications focusing on feasibility and initial proof of concept in Phase I, and optimization and scaling in Phase II. This initiative is crucial for advancing regenerative medicine technologies and addressing challenges in EV therapeutics, ultimately facilitating their application in clinical settings. Eligible applicants can receive funding up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by June 6, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-268.html.
PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), has announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) Grant Applications. This funding opportunity invites eligible U.S. small businesses to submit applications for Phase I, Phase II, Fast-Track, and Direct to Phase II projects that align with the research missions of the NIH, CDC, and FDA, with a focus on stimulating technological innovation and commercialization of federal R&D investments. Notably, applications must not include clinical trials, and funding levels are capped at $306,872 for Phase I and up to $2,045,816 for Phase II, with a submission deadline of April 5, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity through the R21 grant mechanism to support the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate the architectures and functions of the human nervous system. This initiative aims to encourage high-risk, high-reward exploratory research, particularly relevant for addressing complex nervous system disorders, and is open to a diverse range of eligible applicants, including educational institutions, non-profits, and governmental entities. The funding, capped at $275,000 over a two-year period, emphasizes collaboration among experts in neurobiology, engineering, and ethics, and applications must adhere to NIH data management and sharing policies. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 7, 2026.
Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)," aimed at advancing research in human cell-derived microphysiological systems (MPS) that replicate complex nervous system architectures and functions. This initiative seeks innovative applications that address technological barriers in studying nervous system development and diseases, with a focus on improving physiological relevance and circuit-level activity in existing assays. The funding is open to a wide range of eligible applicants, including higher education institutions and non-profits, with a project period of up to five years and no cost-sharing requirement. Interested parties should note that the application deadline is January 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-046.html.